Physician profile
Veronica Lujan
NPI 1225708498
$7,756.14
in general payments reported to CMS, 2019-2025
43 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $454 · 2022: $2,342 · 2023: $1,783 · 2024: $1,859 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,959.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,595.61 | 2021-2025 | |
| Lilly USA, LLC | $764.01 | 2021-2025 | Emgality, Reyvow, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $651.16 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $496.44 | 2023-2025 | |
| Novo Nordisk INC | $348.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $339.04 | 2021-2024 | Nayzilam, Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $314.96 | 2022 | |
| Harmony Biosciences LLC | $276.51 | 2022-2023 | Wakix |
| Biogen, INC. | $260.73 | 2022-2024 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $228.81 | 2021-2024 | |
| Inspire Medical Systems, INC. | $227.14 | 2022-2023 | Inspire |
| Argenx US, INC. | $225.63 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $192.57 | 2022-2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $178.15 | 2021-2024 | |
| Sk Life Science, INC. | $170.95 | 2021-2024 | Xcopri |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $116.13 | 2024 | Dexcom G7 Gss (161) |
| Eisai INC. | $104.25 | 2023-2024 | |
| Neurelis, INC. | $99.01 | 2022 | |
| Horizon Therapeutics Plc | $91.16 | 2022-2023 | Uplizna |
| Idorsia Pharmaceuticals US INC | $88.03 | 2023-2024 | Quviviq |
| Alexion Pharmaceuticals, INC. | $85.94 | 2022-2024 | Ultomiris |
| Amgen INC. | $75.07 | 2022-2024 | Uplizna |
| Genzyme Corporation | $71.39 | 2021 | |
| Acorda Therapeutics, INC | $67.09 | 2023-2024 | Inbrija |
| Emd Serono, INC. | $62.41 | 2022 | |
| Paratek Pharmaceuticals, INC. | $59.88 | 2025 | Nuzyra |
| Neurocrine Biosciences, INC. | $56.35 | 2022 | |
| Averitas Pharma INC. | $55.93 | 2023-2024 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $55.56 | 2021 | |
| Exact Sciences Corporation | $46.30 | 2025 | Cologuard Collection Kit |
| Ge Healthcare | $43.70 | 2021-2023 | |
| Lundbeck LLC | $37.59 | 2022-2023 | Vyepti |
| Upsher-Smith Laboratories LLC | $33.40 | 2021-2022 | |
| Tanabe Pharma America, INC. | $32.57 | 2022-2023 | |
| Glaxosmithkline, LLC. | $30.38 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $29.30 | 2022-2023 | Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $29.05 | 2022 | |
| Allergan, INC. | $27.75 | 2021 | |
| Grifols USA, LLC | $21.61 | 2024 | Gamunex-C |
| Acadia Pharmaceuticals INC | $20.93 | 2022 | |
| Kyowa Kirin, INC. | $17.49 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Lujan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.